Vascular Biogenics : Company Presentation January 2021

VBL Therapeutics

Company Presentation

January 2021

NASDAQ: VBLT

Forward-Looking Statements

To the extent that statements contained in this presentation are not descriptions of historical facts regarding Vascular Biogenics Ltd., they are forward- looking statements reflecting management's current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from those anticipated by such statements. You can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," "intends," or "continue," or the negative of these terms or other comparable terminology. Forward- looking statements contained in this presentation include: (i) the timing of the commencement, progress and receipt of data from pre-clinical studies and clinical trials; (ii) the timing of the commencement, progress and receipt of data from any other clinical trials that we conduct; (iii) our plans for future trials, efficacy or clinical utility of our product candidates; (iv) our plans for future trials; (v) the scope of protection we establish and maintain for intellectual property rights covering our product candidates and our technology; (vi) our ability to obtain and maintain regulatory approval for our product candidates and the timing or likelihood of regulatory filings and approvals for our product candidates; and (vii) expectations relating to the commercialization of our product candidates.

Various factors may cause differences between our expectations and actual results, including unexpected safety or efficacy data, unexpected side effects observed during preclinical studies or in clinical trials, lower than expected enrollment rates in clinical trials, changes in expected or existing competition, changes in the regulatory environment for our drug candidates and our need for future capital, the inability to protect our intellectual property, and the risk that we become a party to unexpected litigation or other disputes. You should read our filings with the Securities and Exchange Commission, including the Risk Factors set forth in our Annual Report on Form 20-F for the year ended December 31, 2019 and our other filings with the Securities and Exchange Commission, completely and with the understanding that our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

2

Why Invest in VBL Therapeutics NOW?

Our Technologies

Three first-in-class breakthrough platform technologies in oncology

• inflammation, ranging from gene-therapy, through oral molecules to monoclonal antibodies.

Team

Strong management and seasoned board members, committed to leading the company to success.

Data

Overall survival benefit demonstrated across four clinical trials. Our OVAL Phase 3 study for VB-111 showed response rate of ≥58% in an interim analysis.

Lead Asset

Phase 3 registration study underway in ovarian cancer, an unmet medical need. Additional indications are in clinical development for solid tumors.

Validation	Upside
International clinical and business	Multiple catalysts expected on the
collaborations, along with strong	way to commercialization of VB-
academic and governmental	111 for multi-billion $ markets.
support.

3

At VBL, We Develop Breakthrough Therapies for Cancer and

Immune-Inflammatory Diseases

Platform	Candidate	Program Area	Preclinical	Phase 1	Phase 2	Phase 3	Status	Partnering
Vascular		Ovarian Cancer (prOC)	Potential Registration Trial			>50% enrolled
Targeting	VB-111	Colorectal Cancer	Nivolumab Combo			Recruiting	Strategic Licensing
System (VTS™)	(ofranergene
Recurrent Glioblastoma					Open for	deal for Japan
	obadenovec)	Investigator Initiated
			enrollment
(gene therapy)
	Thyroid Cancer (RAIR-DTC)	Phase 2 Completed
Anti-MOSPD2	VB-601	Anti-inflammatory					IND enabling
				studies
(mAbs)	VB-611	Immuno-oncology
		Atherosclerosis	Phase 2 Completed				Strategic Licensing
Lecinoxoids
VB-201	NASH					Phase 2 ready	deal for veterinary
(Oral anti		Renal Fibrosis						use
inflammatory		NASH
small molecules)
VB-703
		Renal Fibrosis

4